PACKAGING COORDINATORS, INC. ACQUIRES ANDERSONBRECON FROM AMERISOURCEBERGEN
Combined Business Will Operate Under The Packaging Coordinators Brand Creating The Largest Global Pharmaceutical Contract Packager
May 13, 2013 -- Packaging Coordinators, Inc. today announced that it has completed the acquisition of pharmaceutical packager AndersonBrecon from its parent company AmerisourceBergen Corporation. AndersonBrecon will now merge with and operate as Packaging Coordinators, Inc. (“PCI”).
“We are extremely excited to bring the experience of the AndersonBrecon team to propel our national presence and establish a European footprint for PCI,” said Bill Mitchell, PCI President and Chief Executive Officer. “PCI has been on an aggressive growth track in the last year, focused on providing customers with quality resources and packaging solutions. We will now have a combined operating space of approximately two million square feet, more than 140 commercial and clinical packaging suites, and operations in both the US and UK with over 2,000 associates. Combined, we will now package product for 19 of the top 20 global pharmaceutical/biotechnology companies.”
Investors included Frazier Healthcare, which led the transaction, QIC Global Private Equity, Greenspring Associates and Thomas, McNerney & Partners.
Packaging Coordinators, Inc. offers unparalleled expertise in a range of proprietary pharmaceutical and biotechnology packaging innovations for healthcare clients across all markets. PCI leads the field in providing cutting-edge customized healthcare packaging solutions that improve patient adherence and uphold the most stringent safety requirements. For more information about PCI and its state of the art facilities in Philadelphia, PA and Woodstock, IL, visit the company’s website at
About Thomas, McNerney & Partners
Thomas, McNerney & Partners is a health care venture firm with approximately $600 million under management, focused on investing in innovative life science and medical technology companies at all stages of development. In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization. Thomas, McNerney & Partners also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies, as well as recapitalizations. The firm has offices in Connecticut, Minnesota and California. For further information, please visit
Thomas, McNerney & Partners Contact: Robert C. Perry
Director of Investor Relations